JP7795206B2 - 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用 - Google Patents

条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Info

Publication number
JP7795206B2
JP7795206B2 JP2022577490A JP2022577490A JP7795206B2 JP 7795206 B2 JP7795206 B2 JP 7795206B2 JP 2022577490 A JP2022577490 A JP 2022577490A JP 2022577490 A JP2022577490 A JP 2022577490A JP 7795206 B2 JP7795206 B2 JP 7795206B2
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
antibody fragment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022577490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531189A5 (https=
JP2023531189A (ja
JPWO2021257542A5 (https=
Inventor
ジェイ エム ショート
ガーハード フレイ
フウェイ ウェン チャング
ジン ワン
チャオ シン
Original Assignee
バイオアトラ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオアトラ インコーポレイテッド filed Critical バイオアトラ インコーポレイテッド
Publication of JP2023531189A publication Critical patent/JP2023531189A/ja
Publication of JP2023531189A5 publication Critical patent/JP2023531189A5/ja
Publication of JPWO2021257542A5 publication Critical patent/JPWO2021257542A5/ja
Priority to JP2025247571A priority Critical patent/JP2026053430A/ja
Application granted granted Critical
Publication of JP7795206B2 publication Critical patent/JP7795206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
JP2022577490A 2020-06-18 2021-06-15 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用 Active JP7795206B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025247571A JP2026053430A (ja) 2020-06-18 2025-12-12 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063040913P 2020-06-18 2020-06-18
US63/040,913 2020-06-18
PCT/US2021/037400 WO2021257542A1 (en) 2020-06-18 2021-06-15 Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025247571A Division JP2026053430A (ja) 2020-06-18 2025-12-12 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Publications (4)

Publication Number Publication Date
JP2023531189A JP2023531189A (ja) 2023-07-21
JP2023531189A5 JP2023531189A5 (https=) 2024-06-18
JPWO2021257542A5 JPWO2021257542A5 (https=) 2024-06-18
JP7795206B2 true JP7795206B2 (ja) 2026-01-07

Family

ID=79268294

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022577490A Active JP7795206B2 (ja) 2020-06-18 2021-06-15 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用
JP2025247571A Pending JP2026053430A (ja) 2020-06-18 2025-12-12 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025247571A Pending JP2026053430A (ja) 2020-06-18 2025-12-12 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用

Country Status (11)

Country Link
US (1) US20230242662A1 (https=)
EP (1) EP4168452A4 (https=)
JP (2) JP7795206B2 (https=)
KR (1) KR20230023800A (https=)
CN (1) CN115702167A (https=)
AU (1) AU2021292486A1 (https=)
CA (1) CA3182384A1 (https=)
IL (1) IL298902A (https=)
MX (1) MX2022016197A (https=)
TW (1) TWI906314B (https=)
WO (1) WO2021257542A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544493A (ja) 2010-09-03 2013-12-19 ステム セントリックス, インコーポレイテッド 新規モジュレータ及びその使用法
JP2018534932A (ja) 2015-11-02 2018-11-29 バイオアトラ、エルエルシー 条件的活性型ポリペプチド
JP2019528323A (ja) 2016-08-31 2019-10-10 バイオアトラ、エルエルシー 条件的活性型ポリペプチド及びそれを生成する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CN107135654B (zh) * 2014-09-12 2021-10-29 加利福尼亚大学董事会 巨胞饮人类抗cd46抗体和靶向癌症疗法
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
ES3005158T3 (en) * 2016-11-11 2025-03-14 Univ California Anti-cd46 antibodies and methods of use
CN109535260B (zh) * 2018-11-22 2021-08-10 东南大学 一种靶向cd46的人源嵌合抗原受体及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544493A (ja) 2010-09-03 2013-12-19 ステム セントリックス, インコーポレイテッド 新規モジュレータ及びその使用法
JP2018534932A (ja) 2015-11-02 2018-11-29 バイオアトラ、エルエルシー 条件的活性型ポリペプチド
JP2019528323A (ja) 2016-08-31 2019-10-10 バイオアトラ、エルエルシー 条件的活性型ポリペプチド及びそれを生成する方法

Also Published As

Publication number Publication date
JP2026053430A (ja) 2026-03-25
KR20230023800A (ko) 2023-02-17
IL298902A (en) 2023-02-01
TWI906314B (zh) 2025-12-01
CN115702167A (zh) 2023-02-14
JP2023531189A (ja) 2023-07-21
WO2021257542A1 (en) 2021-12-23
EP4168452A1 (en) 2023-04-26
AU2021292486A1 (en) 2023-02-09
MX2022016197A (es) 2023-04-05
TW202214696A (zh) 2022-04-16
EP4168452A4 (en) 2024-07-10
CA3182384A1 (en) 2021-12-23
US20230242662A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
TWI901704B (zh) 條件活性抗粘附分子-4(nectin-4)抗體
US12427347B2 (en) Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
US20230109218A1 (en) Conditionally Active Anti-Her2 Antibodies, Antibody Fragments Their Immunoconjugates And Uses Thereof
JP7795206B2 (ja) 条件的に活性な抗cd46抗体、抗体断片、それらの免疫コンジュゲート及びその使用
HK40087739A (zh) 条件性活性抗cd46抗体、抗体片段、其免疫结合物及其用途
TW202607039A (zh) 條件性活性抗cd46抗體、抗體片段、其免疫結合物及其用途
HK40089117A (zh) 条件性活性抗her2抗体、抗体片段、其免疫结合物及其用途
TW202604970A (zh) 條件活性抗粘附分子-4(nectin-4)抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251212

R150 Certificate of patent or registration of utility model

Ref document number: 7795206

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150